Dan Kemp Email & Phone

Chief Executive Officer @ Shinobi Therapeutics

Chief Executive Officer @ Wugen

Board Director @ Adaptate Biotherapeutics

Board Director @ GammaDelta Therapeutics

Vice President, Head of Cell Therapies BD and Operations @ Takeda

Sr. Director, Business Development @ Takeda Pharmaceuticals

Senior Vice President of Discovery and Development @ Beryllium

Director, Program Leader (MK-8722) @ Merck Research Laboratories

Associate Director, Target ID and Validation @ Merck & Co., Inc.

Senior Research Investigator @ Novartis

Postdoctoral Fellow | Habener Lab @ Harvard Medical School and Massachusetts General Hospital

Case Student @ Pfizer

2000 - 2003 Post Doctoral Research @ Harvard Medical School - Massachusetts General Hospital

1996 - 1999 PhD @ University of Kent

Lifesciences, Drug Discovery, Biomarkers, Drug Development, Biotechnology, Clinical Development, Assay Development, Cell, Molecular Biology, Clinical Trials, High Throughput Screening, Genetics, Clinical Research, Diabetes, R&D, Validation, Microsoft Word, Microsoft Excel, Data Analysis, Customer Service, Strategic Planning

Dan Kemp, based in New York, NY, US, is currently a Chief Executive Officer at Shinobi Therapeutics. Dan Kemp brings experience from previous roles at Wugen, Adaptate Biotherapeutics, GammaDelta Therapeutics, Takeda, Takeda Pharmaceuticals, Beryllium, Merck Research Laboratories, Merck & Co., Inc., Novartis, Harvard Medical School and Massachusetts General Hospital, Pfizer. Dan Kemp holds various educational qualifications including Post Doctoral Research (2000 - 2003) from Harvard Medical School - Massachusetts General Hospital. With a robust skill set that includes Lifesciences, Drug Discovery, Biomarkers, Drug Development, Biotechnology, Dan Kemp demonstrates proficiency in a wide range of areas.